终末期肾衰竭的未来治疗:基因编辑猪肾异种移植。

IF 3.4 Q1 UROLOGY & NEPHROLOGY
Kidney Medicine Pub Date : 2025-05-30 eCollection Date: 2025-08-01 DOI:10.1016/j.xkme.2025.101041
Liaoran Wang, Maho Terashita, Kohei Kinoshita, Akihiro Maenaka, Ivy A Rosales, David K C Cooper
{"title":"终末期肾衰竭的未来治疗:基因编辑猪肾异种移植。","authors":"Liaoran Wang, Maho Terashita, Kohei Kinoshita, Akihiro Maenaka, Ivy A Rosales, David K C Cooper","doi":"10.1016/j.xkme.2025.101041","DOIUrl":null,"url":null,"abstract":"<p><p>In patients with end-stage kidney disease, kidney transplantation from a living or deceased human donor offers a much-improved quality and length of life. Gene-edited pigs might provide an alternative source of kidneys for clinical transplantation (xenotransplantation). The major pathobiological barriers to successful pig kidney xenotransplantation have steadily been overcome by the following methods: (1) genetic engineering of the organ-source pig and (2) the administration of novel immunosuppressive agents. Pig kidney transplants have now supported immunosuppressed (anephric) nonhuman primates for periods in excess of a year, although this cannot be achieved consistently. The pig kidney graft can fulfill almost all of the functional requirements of a human kidney. The potential risks of infection with a pig microorganism will be minimized by the breeding and housing of the organ-source pigs in biosecure \"clean\" environments. For the first formal clinical trial, we suggest that diabetic patients on the waiting list aged 55-65 years with blood group O or B who are unlikely ever to receive a deceased human donor kidney might accept a pig kidney if it will negate the need for dialysis for 1 or more years.</p>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"7 8","pages":"101041"},"PeriodicalIF":3.4000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12309947/pdf/","citationCount":"0","resultStr":"{\"title\":\"Future Therapy for End-Stage Kidney Failure: Gene-Edited Pig Kidney Xenotransplantation.\",\"authors\":\"Liaoran Wang, Maho Terashita, Kohei Kinoshita, Akihiro Maenaka, Ivy A Rosales, David K C Cooper\",\"doi\":\"10.1016/j.xkme.2025.101041\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In patients with end-stage kidney disease, kidney transplantation from a living or deceased human donor offers a much-improved quality and length of life. Gene-edited pigs might provide an alternative source of kidneys for clinical transplantation (xenotransplantation). The major pathobiological barriers to successful pig kidney xenotransplantation have steadily been overcome by the following methods: (1) genetic engineering of the organ-source pig and (2) the administration of novel immunosuppressive agents. Pig kidney transplants have now supported immunosuppressed (anephric) nonhuman primates for periods in excess of a year, although this cannot be achieved consistently. The pig kidney graft can fulfill almost all of the functional requirements of a human kidney. The potential risks of infection with a pig microorganism will be minimized by the breeding and housing of the organ-source pigs in biosecure \\\"clean\\\" environments. For the first formal clinical trial, we suggest that diabetic patients on the waiting list aged 55-65 years with blood group O or B who are unlikely ever to receive a deceased human donor kidney might accept a pig kidney if it will negate the need for dialysis for 1 or more years.</p>\",\"PeriodicalId\":17885,\"journal\":{\"name\":\"Kidney Medicine\",\"volume\":\"7 8\",\"pages\":\"101041\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12309947/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.xkme.2025.101041\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.xkme.2025.101041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

对于终末期肾病患者,活体或已故人类供体的肾移植可大大提高患者的生活质量和寿命。基因编辑的猪可能为临床移植(异种移植)提供另一种肾脏来源。猪肾异种移植成功的主要病理生物学障碍已经通过以下方法逐步克服:(1)器官源猪的基因工程和(2)新型免疫抑制剂的使用。猪肾移植现在已经支持免疫抑制(无肾)的非人灵长类动物超过一年的时间,尽管这不能一直实现。猪肾移植几乎可以满足人肾的所有功能要求。通过在生物安全的“清洁”环境中饲养和饲养器官源猪,将猪微生物感染的潜在风险降至最低。对于第一个正式的临床试验,我们建议等候名单上年龄在55-65岁的O型或B型血的糖尿病患者,如果他们不太可能接受死者捐献的肾脏,可以接受猪肾,如果它可以在1年或更长时间内消除透析的需要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Future Therapy for End-Stage Kidney Failure: Gene-Edited Pig Kidney Xenotransplantation.

Future Therapy for End-Stage Kidney Failure: Gene-Edited Pig Kidney Xenotransplantation.

Future Therapy for End-Stage Kidney Failure: Gene-Edited Pig Kidney Xenotransplantation.

Future Therapy for End-Stage Kidney Failure: Gene-Edited Pig Kidney Xenotransplantation.

In patients with end-stage kidney disease, kidney transplantation from a living or deceased human donor offers a much-improved quality and length of life. Gene-edited pigs might provide an alternative source of kidneys for clinical transplantation (xenotransplantation). The major pathobiological barriers to successful pig kidney xenotransplantation have steadily been overcome by the following methods: (1) genetic engineering of the organ-source pig and (2) the administration of novel immunosuppressive agents. Pig kidney transplants have now supported immunosuppressed (anephric) nonhuman primates for periods in excess of a year, although this cannot be achieved consistently. The pig kidney graft can fulfill almost all of the functional requirements of a human kidney. The potential risks of infection with a pig microorganism will be minimized by the breeding and housing of the organ-source pigs in biosecure "clean" environments. For the first formal clinical trial, we suggest that diabetic patients on the waiting list aged 55-65 years with blood group O or B who are unlikely ever to receive a deceased human donor kidney might accept a pig kidney if it will negate the need for dialysis for 1 or more years.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Kidney Medicine
Kidney Medicine Medicine-Internal Medicine
CiteScore
4.80
自引率
5.10%
发文量
176
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信